tecartus
kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lümfoom, mantle-cell - antineoplastilised ained - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).
maqs taru ravimriba
nod europe ltd - sipelghape - taru ravimriba - 68,2g 10tk; 68,2g 3tk; 68,2g 2tk; 68,2g 5tk
flixotide diskus 50 mcg inhalatsioonipulber
glaxosmithkline (ireland) limited - flutikasoon - inhalatsioonipulber - 50mcg 1annus 60annus 1tk
serevent diskus 50 mcg inhalatsioonipulber
glaxosmithkline (ireland) limited - salmeterool - inhalatsioonipulber - 50mcg 1annus 60annus 1tk
flixotide diskus 100 mcg inhalatsioonipulber
glaxosmithkline (ireland) limited - flutikasoon - inhalatsioonipulber - 100mcg 1annus 60annus 1tk
flixotide diskus 250 mcg inhalatsioonipulber
glaxosmithkline (ireland) limited - flutikasoon - inhalatsioonipulber - 250mcg 1annus 60annus 1tk